top of page

Nature's Secrets: Cannabis and Mushrooms Pave the Way for Better Health

Today, the Global Cannabinoid Research Center unveiled insights from a groundbreaking study conducted by Johns Hopkins University, examining the effects and dosing of Psilocybin, commonly known as magic mushrooms or 'Shrooms'. Amidst an era of growing interest in plant-based and fungal therapies, the center is broadening its research scope to include psychedelic substances, which are increasingly recognized for their potential in treating mental health disorders.

Mike Robinson, from the Research Center, highlighted the growing trend towards seeking natural means for mental relaxation, noting the occasional side effects like anxiety that some experience during their psychedelic journeys. "Incorporating cannabis, whether THC or hemp extracts, can significantly smooth out these experiences," Robinson remarked, emphasizing the synergy between these natural substances.

The Center's research delves into how Psilocybin interacts with the Endocannabinoid System (ECS), exploring the intricate ways various plant medicines can complement each other. Robinson pointed out the overlooked pain-relief benefits of Psilocybin, attributing it to the mushroom's rich alkaloid content. He argued that such natural remedies offer a respite from the stresses of modern life, including the divisive social and political climate, suggesting that Psilocybin, in conjunction with cannabis, could help mitigate some of the psychological strains prevalent today.

Sharing personal insights, Robinson expressed his cautious stance on the recreational use of Psilocybin, advocating for its medicinal use in line with traditional practices. He emphasized respecting the substance's historical significance and potential for deep psychological exploration and healing.

"Plants and Fungi are the two things I know can keep the human population alive, I have hope in Mother Earth" -Mike Robinson, founder Global Cannabinoid Research Center

The article released by the Research Center follows a recent Johns Hopkins study, which arrives at a pivotal time when psychedelic use is surging, partly driven by the quest for mental health solutions during the pandemic. The study presents compelling evidence for the safety of Psilocybin, while also addressing the complexities of dosing, suggesting that a fixed-dose approach may be more effective than adjusting for individual physical characteristics—a perspective shared with cannabinoid dosing strategies.

The concept of micro-dosing, taking small amounts that do not induce noticeable psychoactive effects, has become widespread. This trend is supported by the decriminalization efforts in various regions, which have reduced legal barriers to Psilocybin use.

Robinson stresses the necessity of ongoing research to fully understand these substances, cautioning against the potential risks of improper dosing due to a lack of education. His work extends beyond cannabinoids to explore the therapeutic potential of psychedelics amidst changing legal landscapes.

Highlighting the importance of an integrated approach to plant medicine, Robinson criticized the binary perspectives that often divide the natural remedy community, advocating for a more inclusive understanding of the benefits of psychoactive substances.

Surveys indicate a high prevalence of concurrent cannabis and Psilocybin use among those seeking natural remedies, suggesting a broader acceptance and curiosity towards plant-based therapies. Robinson envisions a future where the therapeutic laughter and profound insights offered by something as simple as a mushroom will become increasingly sought after, bridging communities and expanding the horizons of plant medicine.


Referenced Research Paper:

First Published February 20, 2021  

Albert Garcia-Romeu et al, John Hopkins University   


Growing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as part of a structured intervention. In most trials to date, psilocybin dose has been administered on a weight-adjusted basis rather than the more convenient procedure of administering a fixed dose. 

Aims: The present post hoc analyses sought to determine whether the subjective effects of psilocybin are affected by body weight when psilocybin is administered on a weight-adjusted basis and when psilocybin is administered as a fixed dose. 

Methods: We analyzed acute subjective drug effects (mystical, challenging, and intensity) associated with therapeutic outcomes from ten previous studies (total N=288) in which psilocybin was administered in the range 20 to 30mg/70 kg (inclusive). Separate multivariate regression analyses examined the relationships between demographic variables including body weight and subjective effects in participants receiving 20mg/70kg (n=120), participants receiving 30mg/70kg (n=182), and participants whose weight-adjusted dose was about 25mg (to approximate the fixed dose that is currently being evaluated in registration trials for major depressive disorder) (n=103). 

Results: In the 20mg/70kg and 30mg/70 kg weight-adjusted groups, and in the fixed dose group, no significant associations were found between subjective effects and demographic variables including body weight or sex. Across a wide range of body weights (49 to 113kg) the present results showed no evidence that body weight affected subjective effects of psilocybin. 

Conclusions: These results suggest that the convenience and lower cost of administering psilocybin as a fixed dose outweigh any potential advantage of weight-adjusted dosing


Barrett FS, Bradstreet MP, Leoutsakos JMS, et al. (2016) The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Journal of Psychopharmacology 30: 1279–1295.


Best sellers

Subscribe to learn more

Join our email list and keep on learning with (ECS) ENDOCARE Supply.

Thanks for submitting!

bottom of page